Papers/PMID:21775755
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.
Diabetes care2011The record
1 finding · 1 compound · 1 endpoint · 1 null
What it reported
How to read these marksEvery finding here is a null result.
What did not
1 finding
lipoic acid — no detected effect on glycated haemoglobin (HbA1c)
Evidence strength: moderate.FindingNull resultreplicated ×1“After 4 years, HbA1c declined compared with baseline by 0.62 ± 1.59% with ALA and by 0.60 ± 1.78% during placebo without significant differences between the groups (P = 0.9313 after 4 years).”
Quoted verbatim from Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.. - Study
- RCT
- Duration
- 4 years
- Dose
- 600 mg ALA once daily (Thioctacid HR film-coated tablet) versus matching placebo
- Population
- Adults aged 18-64 with type 1 or type 2 diabetes and mild-to-moderate distal symmetric sensorimotor polyneuropathy, after 4 years of treatment
Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in diabetic polyneuropathy: the NATHAN 1 trial.2011PMID:2177575510.2337/dc11-0503Permalink